According to the results of the present study, we could postulate that dysregulation of multiple systemic metabolic factors is implicated in KRAS-driven metabolic reprogramming in non recto-sigmoid cancers, whilst in cancers with a distal location serum dyslipidemia may facilitate KRAS related cancer progression. The gene discussed is KRAS; the disease is cancer.